Last reviewed · How we verify
CT-P13 SC Auto-injector
CT-P13 SC Auto-injector is a TNF-alpha inhibitor (monoclonal antibody biosimilar) Biologic drug developed by Celltrion. It is currently in Phase 3 development for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.
CT-P13 SC is a subcutaneous auto-injector formulation of infliximab, a TNF-alpha inhibitor that blocks tumor necrosis factor signaling to reduce inflammation.
CT-P13 SC is a subcutaneous auto-injector formulation of infliximab, a TNF-alpha inhibitor that blocks tumor necrosis factor signaling to reduce inflammation. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.
At a glance
| Generic name | CT-P13 SC Auto-injector |
|---|---|
| Sponsor | Celltrion |
| Drug class | TNF-alpha inhibitor (monoclonal antibody biosimilar) |
| Target | TNF-alpha |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
CT-P13 is a biosimilar of infliximab that binds to and neutralizes TNF-alpha, a key pro-inflammatory cytokine. By blocking TNF-alpha, it suppresses the inflammatory cascade involved in autoimmune and inflammatory diseases. The subcutaneous auto-injector formulation provides a convenient self-administration route compared to intravenous infusion.
Approved indications
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Crohn's disease
- Ulcerative colitis
- Psoriasis
Common side effects
- Injection site reactions
- Infections (including serious infections)
- Headache
- Nausea
- Upper respiratory tract infections
Key clinical trials
- A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis (PHASE3)
- CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT-P13 SC Auto-injector CI brief — competitive landscape report
- CT-P13 SC Auto-injector updates RSS · CI watch RSS
- Celltrion portfolio CI
Frequently asked questions about CT-P13 SC Auto-injector
What is CT-P13 SC Auto-injector?
How does CT-P13 SC Auto-injector work?
What is CT-P13 SC Auto-injector used for?
Who makes CT-P13 SC Auto-injector?
What drug class is CT-P13 SC Auto-injector in?
What development phase is CT-P13 SC Auto-injector in?
What are the side effects of CT-P13 SC Auto-injector?
What does CT-P13 SC Auto-injector target?
Related
- Drug class: All TNF-alpha inhibitor (monoclonal antibody biosimilar) drugs
- Target: All drugs targeting TNF-alpha
- Manufacturer: Celltrion — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Ankylosing spondylitis
- Indication: Drugs for Psoriatic arthritis
- Compare: CT-P13 SC Auto-injector vs similar drugs
- Pricing: CT-P13 SC Auto-injector cost, discount & access